Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma

Leuk Lymphoma. 2018 Jun;59(6):1482-1485. doi: 10.1080/10428194.2017.1376740. Epub 2017 Sep 15.

Authors

Frank Herting¹, Thomas Friess¹, Pablo Umaña², Steven Middleton³, Christian Klein²

Affiliations

¹ a Roche Pharmaceutical Research and Early Development , Roche Innovation Center Munich , Munich , Germany.
² b Roche Pharmaceutical Research and Early Development , Roche Innovation Center Zurich , Zurich , Switzerland.
³ c Roche Pharmaceutical Research and Early Development , Roche Innovation Center New York , New York , USA.

PMID: 28914567
DOI: 10.1080/10428194.2017.1376740

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / pharmacology*
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
Disease Models, Animal
Drug Therapy, Combination
Humans
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / pathology*
Mice
Pyrrolidines / pharmacology*
Sulfonamides / pharmacology*
Xenograft Model Antitumor Assays
para-Aminobenzoates / pharmacology*

Substances

Antibodies, Monoclonal, Humanized
Bridged Bicyclo Compounds, Heterocyclic
Pyrrolidines
RG7388
Sulfonamides
para-Aminobenzoates
venetoclax
obinutuzumab